Immunocore Holdings PLC
NASDAQ:IMCR

Watchlist Manager
Immunocore Holdings PLC Logo
Immunocore Holdings PLC
NASDAQ:IMCR
Watchlist
Price: 32.28 USD 0.5% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Immunocore Holdings PLC?
Write Note

Intrinsic Value

IMCR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one IMCR stock under the Base Case scenario is 118.25 USD. Compared to the current market price of 32.28 USD, Immunocore Holdings PLC is Undervalued by 73%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

IMCR Intrinsic Value
118.25 USD
Undervaluation 73%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Immunocore Holdings PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for IMCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about IMCR?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Immunocore Holdings PLC

Provide an overview of the primary business activities
of Immunocore Holdings PLC.

What unique competitive advantages
does Immunocore Holdings PLC hold over its rivals?

What risks and challenges
does Immunocore Holdings PLC face in the near future?

Has there been any significant insider trading activity
in Immunocore Holdings PLC recently?

Summarize the latest earnings call
of Immunocore Holdings PLC.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Immunocore Holdings PLC.

Provide P/S
for Immunocore Holdings PLC.

Provide P/E
for Immunocore Holdings PLC.

Provide P/OCF
for Immunocore Holdings PLC.

Provide P/FCFE
for Immunocore Holdings PLC.

Provide P/B
for Immunocore Holdings PLC.

Provide EV/S
for Immunocore Holdings PLC.

Provide EV/GP
for Immunocore Holdings PLC.

Provide EV/EBITDA
for Immunocore Holdings PLC.

Provide EV/EBIT
for Immunocore Holdings PLC.

Provide EV/OCF
for Immunocore Holdings PLC.

Provide EV/FCFF
for Immunocore Holdings PLC.

Provide EV/IC
for Immunocore Holdings PLC.

Show me price targets
for Immunocore Holdings PLC made by professional analysts.

What are the Revenue projections
for Immunocore Holdings PLC?

How accurate were the past Revenue estimates
for Immunocore Holdings PLC?

What are the Net Income projections
for Immunocore Holdings PLC?

How accurate were the past Net Income estimates
for Immunocore Holdings PLC?

What are the EPS projections
for Immunocore Holdings PLC?

How accurate were the past EPS estimates
for Immunocore Holdings PLC?

What are the EBIT projections
for Immunocore Holdings PLC?

How accurate were the past EBIT estimates
for Immunocore Holdings PLC?

Compare the revenue forecasts
for Immunocore Holdings PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Immunocore Holdings PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Immunocore Holdings PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Immunocore Holdings PLC compared to its peers.

Compare the P/E ratios
of Immunocore Holdings PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Immunocore Holdings PLC with its peers.

Analyze the financial leverage
of Immunocore Holdings PLC compared to its main competitors.

Show all profitability ratios
for Immunocore Holdings PLC.

Provide ROE
for Immunocore Holdings PLC.

Provide ROA
for Immunocore Holdings PLC.

Provide ROIC
for Immunocore Holdings PLC.

Provide ROCE
for Immunocore Holdings PLC.

Provide Gross Margin
for Immunocore Holdings PLC.

Provide Operating Margin
for Immunocore Holdings PLC.

Provide Net Margin
for Immunocore Holdings PLC.

Provide FCF Margin
for Immunocore Holdings PLC.

Show all solvency ratios
for Immunocore Holdings PLC.

Provide D/E Ratio
for Immunocore Holdings PLC.

Provide D/A Ratio
for Immunocore Holdings PLC.

Provide Interest Coverage Ratio
for Immunocore Holdings PLC.

Provide Altman Z-Score Ratio
for Immunocore Holdings PLC.

Provide Quick Ratio
for Immunocore Holdings PLC.

Provide Current Ratio
for Immunocore Holdings PLC.

Provide Cash Ratio
for Immunocore Holdings PLC.

What is the historical Revenue growth
over the last 5 years for Immunocore Holdings PLC?

What is the historical Net Income growth
over the last 5 years for Immunocore Holdings PLC?

What is the current Free Cash Flow
of Immunocore Holdings PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Immunocore Holdings PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Immunocore Holdings PLC

Current Assets 956.9m
Cash & Short-Term Investments 859.6m
Receivables 60.2m
Other Current Assets 37m
Non-Current Assets 66.5m
Long-Term Investments 16.3m
PP&E 40.1m
Other Non-Current Assets 10.1m
Current Liabilities 185.1m
Accounts Payable 19.9m
Accrued Liabilities 165.1m
Non-Current Liabilities 479.1m
Long-Term Debt 438.1m
Other Non-Current Liabilities 41m
Efficiency

Earnings Waterfall
Immunocore Holdings PLC

Revenue
460.7m GBP
Cost of Revenue
-3.3m GBP
Gross Profit
457.4m GBP
Operating Expenses
-560.4m GBP
Operating Income
-103m GBP
Other Expenses
14.1m GBP
Net Income
-88.9m GBP

Free Cash Flow Analysis
Immunocore Holdings PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the first half of 2024, net sales of KIMMTRAK reached $146 million, a 34% increase year-over-year. The second quarter alone brought in $75.3 million, mainly due to an 11% growth in the U.S., achieving a 65% market share. KIMMTRAK is now available in 19 countries, with further launches in Poland and Sweden anticipated. Despite a challenging reimbursement environment in Europe, global revenue continues to rise. The company is progressing with Phase III trials for KIMMTRAK in advanced cutaneous melanoma, which could extend its benefits to up to 6,000 patients.

What is Earnings Call?
Fundamental Scores

IMCR Profitability Score
Profitability Due Diligence

Immunocore Holdings PLC's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional 1-Year Revenue Growth
ROE is Increasing
36/100
Profitability
Score

Immunocore Holdings PLC's profitability score is 36/100. The higher the profitability score, the more profitable the company is.

IMCR Solvency Score
Solvency Due Diligence

Immunocore Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Average D/E
41/100
Solvency
Score

Immunocore Holdings PLC's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMCR Price Targets Summary
Immunocore Holdings PLC

Wall Street analysts forecast IMCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMCR is 69.09 USD with a low forecast of 24.24 USD and a high forecast of 105 USD.

Lowest
Price Target
24.24 USD
25% Downside
Average
Price Target
69.09 USD
114% Upside
Highest
Price Target
105 USD
225% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for IMCR?

Click here to dive deeper.

Dividends

Immunocore Holdings PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for IMCR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

IMCR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

IMCR News

Other Videos

Profile

Immunocore Holdings PLC Logo
Immunocore Holdings PLC

Country

United Kingdom

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

Immunocore Holdings Plc operates as a holding company. The company is headquartered in Abingdon, Oxfordshire and currently employs 324 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in the development of TCR bispecific immunotherapies called Immune mobilizing monoclonal TCRs Against X disease (ImmTAX) designed to treat diseases, including cancer, infectious and autoimmune. The firm is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s pipeline is leveraging ImmTAX platform within three therapeutic areas: oncology, infectious disease and autoimmune disease. Its product candidate KIMMTRAK is used for positive adult patients with unresectable or metastatic uveal melanoma (mUM) having demonstrated in Phase III clinical trial.

Contact

OXFORDSHIRE
Abingdon
90 Park Drive, Milton Park, Abingdon
+441235438600.0
www.immunocore.com

IPO

2021-02-05

Employees

324

Officers

CEO & Executive Director
Dr. Bahija Jallal Ph.D.
Executive VP, CFO & Strategy
Mr. Brian R. Di Donato M.B.A.
Chief Human Resources Officer
Ms. Tina St. Leger
Executive Vice President of Research & Development
Dr. David Berman M.D., Ph.D.
SVP & Chief Operating Officer
Mr. John Trainer M.B.A.
SVP, Finance & Chief Accounting Officer
Mr. John Goll III
Show More
Senior VP, CTO and Research & UK Site Lead
Ms. Annelise Vuidepot Ph.D.
VP & Chief Information Officer
Mr. Sean D. Buckley
Head of Investor Relations
Clayton Robertson
Senior VP, General Counsel & Company Secretary
Ms. Lily Margaret Hepworth
Show Less

See Also

Discover More
What is the Intrinsic Value of one IMCR stock?

The intrinsic value of one IMCR stock under the Base Case scenario is 118.25 USD.

Is IMCR stock undervalued or overvalued?

Compared to the current market price of 32.28 USD, Immunocore Holdings PLC is Undervalued by 73%.

Back to Top